Immunomodulatory drugs in sepsis: a systematic review and meta-analysis

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Dysregulation of the host immune response has a central role in the pathophysiology of sepsis. There has been much interest in immunomodulatory drugs as potential therapeutic adjuncts in sepsis. We conducted a systematic review and meta-analysis of randomised controlled trials evaluating the safety and clinical effectiveness of immunomodulatory drugs as adjuncts to standard care in the treatment of adults with sepsis. Our primary outcomes were serious adverse events and all-cause mortality. Fifty-six unique, eligible randomised controlled trials were identified, assessing a range of interventions including cytokine inhibitors; anti-inflammatories; immune cell stimulators; platelet pathway inhibitors; and complement inhibitors. At 1-month follow-up, the use of cytokine inhibitors was associated with a decreased risk of serious adverse events, based on 11 studies involving 7138 patients (RR (95%CI) 0.95 (0.90–1.00), I2 = 0%). The only immunomodulatory drugs associated with an increased risk of serious adverse events were toll-like receptor 4 antagonists (RR (95%CI) 1.18 (1.04–1.34), I2 = 0% (two trials, 567 patients)). Based on 18 randomised controlled trials, involving 11,075 patients, cytokine inhibitors reduced 1-month mortality (RR (95%CI) 0.88 (0.78–0.98), I2 = 57%). Mortality reduction was also shown in the subgroup of 13 randomised controlled trials that evaluated anti-tumour necrosis factor α interventions (RR (95%CI) 0.93 (0.87–0.99), I2 = 0%). Anti-inflammatory drugs had the largest apparent effect on mortality at 2 months at any dose (two trials, 228 patients, RR (95%CI) 0.64 (0.51–0.80), I2 = 0%) and at 3 months at any dose (three trials involving 277 patients, RR (95%CI) 0.67 (0.55–0.81), I2 = 0%). These data indicate that, except for toll-like receptor 4 antagonists, there is no evidence of safety concerns for the use of immunomodulatory drugs in sepsis, and they may show some short-term mortality benefit for selected drugs.

References Powered by Scopus

Cochrane handbook for systematic reviews of interventions

36075Citations
N/AReaders
Get full text

The third international consensus definitions for sepsis and septic shock (sepsis-3)

18003Citations
N/AReaders
Get full text

RoB 2: A revised tool for assessing risk of bias in randomised trials

15527Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Targeting Sepsis: Disease Tolerance, Immune Resilience, and Compartmentalized Immunity

0Citations
N/AReaders
Get full text

It ain't what you do (it's the way that you do it): modulating the host response in sepsis

0Citations
N/AReaders
Get full text

Personalized, disease-stage specific, rapid identification of immunosuppression in sepsis

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Robey, R. C., Logue, C., Caird, C. A., Hansel, J., Hellyer, T. P., Simpson, J., … Felton, T. (2024, August 1). Immunomodulatory drugs in sepsis: a systematic review and meta-analysis. Anaesthesia. John Wiley and Sons Inc. https://doi.org/10.1111/anae.16263

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

100%

Readers' Discipline

Tooltip

Engineering 1

33%

Medicine and Dentistry 1

33%

Immunology and Microbiology 1

33%

Save time finding and organizing research with Mendeley

Sign up for free